
Ligand Pharmaceuticals (LGND) Stock Forecast & Price Target
Ligand Pharmaceuticals (LGND) Analyst Ratings
Bulls say
Ligand Pharmaceuticals Inc. demonstrates a strong financial outlook supported by substantial cash inflows, which facilitate ongoing deal-making and enhance the company's compounding business model within the smid-cap biotech sector. The anticipated successful launches of its products Filspari and Ohtuvayre further contribute to revenue growth, alongside stable returns from established contributors. Overall, Ligand's diversified revenue streams, including royalties, license and milestone payments, and sales of its Captisol material, position the company favorably for sustained financial performance.
Bears say
Ligand Pharmaceuticals Inc. faces a negative outlook primarily due to concerns regarding the potential underperformance of its royalty assets and challenges to the intellectual property durability of key products. The risk of clinical-stage royalty assets not receiving approval amplifies uncertainty around future revenue streams, while anticipated less favorable terms in partnerships could further strain their business model. Additionally, commercial partners may encounter unforeseen difficulties, which could hinder overall financial performance and growth prospects for Ligand.
This aggregate rating is based on analysts' research of Ligand Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.
Ligand Pharmaceuticals (LGND) Analyst Forecast & Price Prediction
Start investing in Ligand Pharmaceuticals (LGND)
Order type
Buy in
Order amount
Est. shares
0 shares